Other languages Abliva AB Deutsche Boerse AG

Equities

NTP

SE0002575340

Delayed Deutsche Boerse AG Other stock markets 01:16:25 17/07/2024 pm IST			5-day change	1st Jan Change
0.0128 ^EUR	+0.79%		+70.67%	+4.07%

30/05	Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	MT
30/05	Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	30/05
Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	30/05
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2024	23/05
Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23/02
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	20/12
EU Commission Grants Orphan Drug Designation to Abliva’s Mitochondrial Disease Drug Candidate; Stock Jumps	14/12
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
Abliva AB and Owl Therapeutics Enter into Licensing and Collaboration Agreement for NeuroSTAT in Traumatic Brain Injury	15/11
Abliva AB Achieves Important Milestone in the Ongoing FALCON Study	11/23/11
Abliva Rises 28% on US FDA Fast Track Designation for Mitochondrial Disease Drug Candidate	04/23/04
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/23/18
Abliva AB Announces First Patient Dosed in the Falcon Study	28/23/28
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23
Abliva AB Announces Resignation of Edwin Moses as Director	04/23/04
Abliva Up 15% on US FDA's Orphan Designation for Mitochondrial Disease Treatment Candidate	17/23/17
Abliva AB Elects Edwin Moses as New Board Member	08/23/08
Abliva AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	24/23/24
Abliva AB Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24
Abliva Starts Mid-stage Study Of Rare Metabolical Disease Drug	06/22/06
Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333	06/22/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Abliva AB Deutsche Boerse AG

Equities

NTP

SE0002575340

Other languages

Filters